Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…
XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL…
June 02, 2025 19:30 ET | Source: Semilux International Ltd. Taipei, Taiwan, June 02, 2025 (GLOBE NEWSWIRE) -- Semilux International…